Lecture
Refining Mass Spectrometry-based Plasma Proteomics for Biomarker Discovery
- at -
- ICM Saal 4a
- Type: Lecture
Lecture description
Introduction to Plasma Proteomics
Blood plasma represents one of the most information-rich yet analytically demanding biological matrices available to researchers and clinicians. As a window into the physiological and pathological state of virtually every tissue, the circulating proteome
holds extraordinary promise—yet its complexity has frustrated comprehensive characterization for decades. Proteins in plasma span more than 10 orders of magnitude in abundance, from structural and transport proteins like albumin and immunoglobulins to low-abundance signaling molecules, tissue-leakage products, and candidate biomarkers at vanishingly small concentrations.
Technological Advances
Mass spectrometry-based proteomics has matured into a transformative tool, enabling large-scale studies of hundreds or thousands of samples for population-scale proteome profiling, correlating quantitative protein patterns with phenotypic, clinical, and molecular data in health and disease. Realizing this in discovery projects demands technological progress and reimagined analytical workflows.
The circulating proteome reflects integrated tissue output, immune responses, metabolism, and exposures; intraindividual stability contrasts with substantial interindividual variability. Complementary strategies are essential for required insight.
Key Discussion Points
This talk addresses plasma proteomics challenges: pre-analytical variables like centrifugation delay, freeze-thaw cycles, hemolysis, and platelet contamination introduce irreproducible variability often underappreciated. It provides an integrated overview of recent advances in coverage, throughput, and translatability, plus persistent hurdles from abundance dynamics to statistical and infrastructural needs.
Blood plasma represents one of the most information-rich yet analytically demanding biological matrices available to researchers and clinicians. As a window into the physiological and pathological state of virtually every tissue, the circulating proteome
holds extraordinary promise—yet its complexity has frustrated comprehensive characterization for decades. Proteins in plasma span more than 10 orders of magnitude in abundance, from structural and transport proteins like albumin and immunoglobulins to low-abundance signaling molecules, tissue-leakage products, and candidate biomarkers at vanishingly small concentrations.
Technological Advances
Mass spectrometry-based proteomics has matured into a transformative tool, enabling large-scale studies of hundreds or thousands of samples for population-scale proteome profiling, correlating quantitative protein patterns with phenotypic, clinical, and molecular data in health and disease. Realizing this in discovery projects demands technological progress and reimagined analytical workflows.
The circulating proteome reflects integrated tissue output, immune responses, metabolism, and exposures; intraindividual stability contrasts with substantial interindividual variability. Complementary strategies are essential for required insight.
Key Discussion Points
This talk addresses plasma proteomics challenges: pre-analytical variables like centrifugation delay, freeze-thaw cycles, hemolysis, and platelet contamination introduce irreproducible variability often underappreciated. It provides an integrated overview of recent advances in coverage, throughput, and translatability, plus persistent hurdles from abundance dynamics to statistical and infrastructural needs.
